Ionis Pharmaceuticals Announces Positive Phase 3 Study Results

Ionis Pharmaceuticals ( (IONS) ) has provided an update.

On September 2, 2025, Ionis Pharmaceuticals announced positive results from its Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG). The studies revealed significant reductions in fasting triglycerides and acute pancreatitis events, positioning olezarsen as a potential new standard for sHTG treatment. The results demonstrated a 72% reduction in triglycerides and an 85% reduction in pancreatitis events, with favorable safety and tolerability. Ionis plans to submit a supplemental new drug application to the FDA by the end of the year, marking a significant step in their efforts to address sHTG and expand their market presence.

The most recent analyst rating on (IONS) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Ionis Pharmaceuticals stock, see the IONS Stock Forecast page.

Spark’s Take on IONS Stock

According to Spark, TipRanks’ AI Analyst, IONS is a Neutral.

Ionis Pharmaceuticals’ overall stock score reflects significant financial challenges, including high leverage and negative cash flows, which weigh heavily on the score. However, strong earnings call results and recent FDA approval for DAWNZERA provide a positive outlook, indicating potential for future growth. Technical indicators suggest moderate bullish momentum, but valuation remains a concern due to ongoing losses.

To see Spark’s full report on IONS stock, click here.

More about Ionis Pharmaceuticals

Ionis Pharmaceuticals is a pioneer in RNA-targeted medicines, with a focus on neurology, cardiometabolic disease, and other areas of high patient need. The company is known for its innovative approaches in RNA therapies and gene editing, aiming to deliver transformative care for serious diseases.

Average Trading Volume: 1,912,358

Technical Sentiment Signal: Buy

Current Market Cap: $6.8B

Learn more about IONS stock on TipRanks’ Stock Analysis page.